A Multicenter, Single-arm, Phase Ⅱ Clinical Trial of Apatinib Monotherapy in Elderly Patients With Advanced Gastric Cancer(GC)
Latest Information Update: 17 Mar 2022
Price :
$35 *
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 02 Jul 2021 Status changed from recruiting to completed.
- 04 Jul 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2019.
- 22 Aug 2017 Status changed from not yet recruiting to recruiting.